AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 19.1 Million EUR | -20.27% |
| 2022 | 23.95 Million EUR | 186.84% |
| 2021 | 8.35 Million EUR | 18.32% |
| 2020 | 7.05 Million EUR | 248.94% |
| 2019 | 2.02 Million EUR | 11800.0% |
| 2018 | 17 Thousand EUR | -99.82% |
| 2017 | 9.33 Million EUR | -24.45% |
| 2016 | 12.35 Million EUR | -44.15% |
| 2015 | 22.12 Million EUR | -4.86% |
| 2014 | 23.25 Million EUR | 2.32% |
| 2013 | 22.72 Million EUR | 1170.43% |
| 2012 | 1.78 Million EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.92 Million EUR | 0.0% |
| 2023 FY | 19.1 Million EUR | -20.27% |
| 2023 Q2 | 19.36 Million EUR | -1.24% |
| 2023 Q4 | 19.1 Million EUR | 1.58% |
| 2023 Q3 | 18.8 Million EUR | -2.92% |
| 2023 Q1 | 19.61 Million EUR | -18.14% |
| 2022 Q1 | 20.33 Million EUR | 143.49% |
| 2022 Q3 | 27.37 Million EUR | 67.37% |
| 2022 Q4 | 23.95 Million EUR | -12.5% |
| 2022 FY | 23.95 Million EUR | 186.84% |
| 2022 Q2 | 16.35 Million EUR | -19.56% |
| 2021 Q2 | 8.59 Million EUR | 0.84% |
| 2021 Q3 | 14.69 Million EUR | 70.96% |
| 2021 FY | 8.35 Million EUR | 18.32% |
| 2021 Q4 | 8.35 Million EUR | -43.17% |
| 2021 Q1 | 8.52 Million EUR | 20.75% |
| 2020 Q2 | 6.54 Million EUR | -67.92% |
| 2020 Q4 | 7.05 Million EUR | -63.88% |
| 2020 Q1 | 20.38 Million EUR | 907.81% |
| 2020 Q3 | 19.54 Million EUR | 198.82% |
| 2020 FY | 7.05 Million EUR | 248.94% |
| 2019 Q2 | 1.55 Million EUR | -88.91% |
| 2019 Q4 | 2.02 Million EUR | -85.59% |
| 2019 Q3 | 14.03 Million EUR | 801.41% |
| 2019 Q1 | 14.03 Million EUR | 82476.46% |
| 2019 FY | 2.02 Million EUR | 11800.0% |
| 2018 Q2 | 9.33 Million EUR | 17.04% |
| 2018 FY | 17 Thousand EUR | -99.82% |
| 2018 Q4 | 17 Thousand EUR | -99.79% |
| 2018 Q3 | 8.21 Million EUR | -12.01% |
| 2018 Q1 | 7.97 Million EUR | -14.56% |
| 2017 Q3 | 11.05 Million EUR | 18.39% |
| 2017 Q4 | 9.33 Million EUR | -15.55% |
| 2017 Q1 | 12.14 Million EUR | -1.74% |
| 2017 Q2 | 9.33 Million EUR | -23.1% |
| 2017 FY | 9.33 Million EUR | -24.45% |
| 2016 Q1 | 13.21 Million EUR | -40.29% |
| 2016 FY | 12.35 Million EUR | -44.15% |
| 2016 Q4 | 12.35 Million EUR | -0.06% |
| 2016 Q3 | 12.36 Million EUR | -6.34% |
| 2016 Q2 | 13.2 Million EUR | -0.07% |
| 2015 Q4 | 22.12 Million EUR | -0.04% |
| 2015 FY | 22.12 Million EUR | -4.86% |
| 2015 Q3 | 22.13 Million EUR | -6.34% |
| 2015 Q1 | 23.64 Million EUR | 1.65% |
| 2015 Q2 | 23.63 Million EUR | -0.03% |
| 2014 Q4 | 23.25 Million EUR | -0.03% |
| 2014 Q2 | 23.06 Million EUR | 0.0% |
| 2014 Q1 | 23.06 Million EUR | 1.47% |
| 2014 FY | 23.25 Million EUR | 2.32% |
| 2014 Q3 | 23.26 Million EUR | 0.88% |
| 2013 Q1 | 22.47 Million EUR | 1156.23% |
| 2013 Q2 | 22.47 Million EUR | 0.0% |
| 2013 Q3 | 22.72 Million EUR | 1.13% |
| 2013 Q4 | 22.72 Million EUR | 0.0% |
| 2013 FY | 22.72 Million EUR | 1170.43% |
| 2012 Q4 | 1.78 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 1.78 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | 6.12 Million EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Boiron SA | 13.7 Million EUR | -39.403% |
| Laboratorios Farmaceuticos Rovi, S.A. | 46.63 Million EUR | 59.041% |
| Vetoquinol SA | 17.62 Million EUR | -8.356% |
| Valneva SE | 208.81 Million EUR | 90.853% |
| Nanobiotix S.A. | 45.48 Million EUR | 58.004% |
| PHAXIAM Therapeutics S.A. | 10.19 Million EUR | -87.283% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -50165.789% |
| BioSenic S.A. | 28.16 Million EUR | 32.172% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 65.561% |
| Formycon AG | 29.48 Million EUR | 35.22% |